WuXi Biologics (Cayman) Inc. (2269.HK)
- Previous Close
14.560 - Open
14.660 - Bid 14.060 x --
- Ask 14.080 x --
- Day's Range
14.020 - 14.720 - 52 Week Range
12.420 - 52.450 - Volume
79,338,632 - Avg. Volume
61,944,809 - Market Cap (intraday)
58.46B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
16.94 - EPS (TTM)
0.830 - Earnings Date Mar 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.61
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
www.wuxibiologics.comRecent News: 2269.HK
Performance Overview: 2269.HK
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2269.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2269.HK
Valuation Measures
Market Cap
58.46B
Enterprise Value
51.23B
Trailing P/E
16.88
Forward P/E
12.56
PEG Ratio (5yr expected)
0.84
Price/Sales (ttm)
3.32
Price/Book (mrq)
1.34
Enterprise Value/Revenue
2.78
Enterprise Value/EBITDA
8.61
Financial Highlights
Profitability and Income Statement
Profit Margin
19.96%
Return on Assets (ttm)
4.63%
Return on Equity (ttm)
8.90%
Revenue (ttm)
17.03B
Net Income Avi to Common (ttm)
3.4B
Diluted EPS (ttm)
0.830
Balance Sheet and Cash Flow
Total Cash (mrq)
11.24B
Total Debt/Equity (mrq)
10.36%
Levered Free Cash Flow (ttm)
-320.31M
Research Analysis: 2269.HK
Company Insights: 2269.HK
2269.HK does not have Company Insights